Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Share Options

31 Aug 2011 14:44

RNS Number : 3548N
Angle PLC
31 August 2011
 



For immediate release

31 August 2011

 

ANGLE plc ("the Company")

 

Share Options

 

Reflecting the current developments within the business and the need to ensure ongoing incentivisation of the management team, the Remuneration Committee has cancelled certain existing share options over ordinary shares in the Company issued to staff and directors and issued new share options at the current market price.

 

Following the cancellation of 940,422 existing share options and the issue of 1,856,000 new share options, the Company now has outstanding options issued to staff and directors over a total of 2,055,397 ordinary shares being 5.8% of the shares currently in issue.

 

The exercise price for the new share options is set at the current mid market price of 25.75 pence per share. Vesting of the share options will be subject to a performance condition that the share price together with any dividend payments has risen by at least 50% from the current market price. The share options will vest over a three year period and expire ten years after issue.

 

Following the new issue of share options, the total number of share options held by the directors and senior management of the Company are:

 

Options (% issued)

Before issue

After issue

Increase

Andrew Newland, Chief Executive

648,675 (1.8%)

950,000 (2.7%)

301,325 (0.8%)

Ian Griffiths, Finance Director

247,619 (0.7%)

500,000 (1.4%)

252,381 (0.7%)

Shane Booth, Parsortix CEO

33,810 (0.1%)

250,000 (0.7%)

216,190 (0.6%)

 

 

The non-executive directors do not hold share options.

 

ANGLE Chairman, Garth Selvey, commented:

"The new options are part of a revitalised remuneration scheme which takes account of changes within the Company and replace four sets of options awarded between 2005 and 2007. The new options also take into account salary waived by senior members of the Company."

 

 

For further information:

ANGLE plc

01483 685830

Garth Selvey, Chairman

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

Collins Stewart Europe Limited

Matt Goode

0207 523 8350

Buchanan

Lisa Baderoon, Catherine Breen

020 7466 5000

Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee

0207 653 0030

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDKDDQNBKDNFN
Date   Source Headline
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting
21st Oct 20226:15 pmRNSIssue of Equity
18th Oct 20227:00 amRNSStreamlining of operations to increase cash runway
17th Oct 20222:23 pmRNSTR-1: Notification of major holdings
12th Oct 20227:00 amRNSFirst regional distribution agreement
30th Sep 20225:30 pmRNSIssue of Equity
30th Sep 20225:30 pmRNSHolding(s) in Company
29th Sep 20227:00 amRNSInterim Results
29th Sep 20227:00 amRNSPositive headline results from ovarian study
28th Sep 20227:00 amRNSStudy using Parsortix in head and neck cancer
13th Sep 20227:00 amRNSNew poster presented at ASCP Meeting
12th Sep 20227:30 amRNSNovel assay predicts malignancy in pelvic mass
1st Sep 20227:00 amRNSNotice of Interim Results and Webcast

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.